Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lucid Group Inc (LCID) vs Moderna, Inc. (MRNA) Price & Performance

Lucid Group IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Lucid Group Inc vs Moderna, Inc. — how do they compare? Lucid Group Inc trades at $6.46 (market cap $2.64B), while Moderna, Inc. trades at $63.78 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 9.2× Lucid Group Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.

LCIDMRNA
Market Cap
$2.64B$24.18B
Sector
Consumer CyclicalHealth
52-Week High
$24.77$81.80
52-Week Low
$4.62$22.36
Enterprise Value
$5.54B$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lucid Group Inc

Lucid (LCID) trades at $6.495, down 1.74% on the day, amid a bearish technical signal and weak fundamentals. The company reported a Q2 2026 EPS miss of -$3.30 versus -$2.41 expected, with revenue growth overshadowed by negative gross and net income margins. Recent news highlights an operational reset targeting $1.4 billion in cash savings and a delayed EV launch, reflecting ongoing challenges in the competitive EV market.

The outlook remains high-risk due to persistent losses and cash burn, though analyst consensus suggests modest upside to a $10.50 price target. Investment opportunities hinge on successful cost-cutting and robotaxi initiatives, while risks include execution missteps and intense competition. With 66.7% of analysts rating Hold, cautious optimism is tempered by financial instability.

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lucid Group Inc

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.

Read more on LCID

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA